GLP-1 use linked to lower breast cancer incidence in large cohort study

A Penn Medicine retrospective analysis of over 110,000 women found that those taking GLP-1 medications were approximately 30 percent less likely to develop breast cancer compared to non-users. The research was presented at the 2026 ASCO Annual Meeting and published in JCO Oncology Practice. While the study does not definitively confirm causation, it suggests GLP-1 drugs warrant further investigation as potential cancer prevention tools.